{"title":"间变性甲状腺癌中ALK重排:个性化治疗的新发现?","authors":"E. Blais, A. Dutertre, Y. Godbert","doi":"10.4172/2155-9619.1000275","DOIUrl":null,"url":null,"abstract":"Anaplastic thyroid carcinoma (ATC) represents about 1% of all thyroid carcinomas [1]. ATC is the most aggressive form of thyroid carcinoma especially when metastatic accounting for 14-50% of all thyroid cancer related deaths [2]. Prognosis and outcomes following local progression or metastasis are poor using conventional therapies such as surgery, chemotherapy, and external beam radiation therapy with only 20% survival at 1 year [3]. So far, previous attempts to use multi-target tyrosine kinase inhibitors have not improved survival outcomes [4]. Therefore, molecular screening for specific genetic alterations in ATC tumors may provide an opportunity for an efficient, targeted therapy.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"193 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2016-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":"{\"title\":\"ALK Rearrangement in Anaplastic Thyroid Carcinoma: A Discovery Towards a Personalized Approach?\",\"authors\":\"E. Blais, A. Dutertre, Y. Godbert\",\"doi\":\"10.4172/2155-9619.1000275\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Anaplastic thyroid carcinoma (ATC) represents about 1% of all thyroid carcinomas [1]. ATC is the most aggressive form of thyroid carcinoma especially when metastatic accounting for 14-50% of all thyroid cancer related deaths [2]. Prognosis and outcomes following local progression or metastasis are poor using conventional therapies such as surgery, chemotherapy, and external beam radiation therapy with only 20% survival at 1 year [3]. So far, previous attempts to use multi-target tyrosine kinase inhibitors have not improved survival outcomes [4]. Therefore, molecular screening for specific genetic alterations in ATC tumors may provide an opportunity for an efficient, targeted therapy.\",\"PeriodicalId\":302578,\"journal\":{\"name\":\"Journal of Nuclear Medicine and Radiation Therapy\",\"volume\":\"193 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"4\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Nuclear Medicine and Radiation Therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.4172/2155-9619.1000275\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Nuclear Medicine and Radiation Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/2155-9619.1000275","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
ALK Rearrangement in Anaplastic Thyroid Carcinoma: A Discovery Towards a Personalized Approach?
Anaplastic thyroid carcinoma (ATC) represents about 1% of all thyroid carcinomas [1]. ATC is the most aggressive form of thyroid carcinoma especially when metastatic accounting for 14-50% of all thyroid cancer related deaths [2]. Prognosis and outcomes following local progression or metastasis are poor using conventional therapies such as surgery, chemotherapy, and external beam radiation therapy with only 20% survival at 1 year [3]. So far, previous attempts to use multi-target tyrosine kinase inhibitors have not improved survival outcomes [4]. Therefore, molecular screening for specific genetic alterations in ATC tumors may provide an opportunity for an efficient, targeted therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
